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Abstract: Fusion of the HIV envelope with the target cell membrane is a critical step of the HIV entry into the target cell. Several
peptides based on the C-region of HIV gp41 have been used in clinical trials as possible HIV fusion inhibitors. Among these are
T-1249 and T-20 (also known as enfurvitide). Despite recent works, a detailed molecular picture of the inhibitory mechanism of
these molecules is still lacking. These peptides are usually depicted as α-helices by analogy with the structure of the sequence of
the gp41 protein with which they are homologous. However, structures like these would be highly unstable in solution and thus
would not explain, by themselves, the ability that the two fusion inhibitors have to become solvated by water and also interact
effectively with cell membranes. To this effect, extensive molecular dynamics simulations were carried out to investigate the
structure and conformational behavior of T-1249 and T-20 in water, as well as shorter homologous peptides CTP and 3f5, which
show no inhibitory action. We found that the studied inhibitors have no stable structure in solution in the time scale studied.
Additionally, the solvent accessible area varies significantly during the simulation. Our findings suggest that these peptides may
assume not only one, but several possible sets of structures in solution, some of which more adequate to interact with the
solvent, whereas others might be better suited to interact with cell membranes. Interestingly, and in accordance with published
experimental studies, we verified that T-1249 displays considerably larger α-helical structure than T-20. Taking into account a
recent study with design peptides with increased helicity, it is possible that this feature may be related to the increased inhibiting
efficiency of T-1249 relative to that of T-20. Copyright  2007 European Peptide Society and John Wiley & Sons, Ltd.
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INTRODUCTION
Membrane fusion between enveloped viruses and
host cell membranes is an obligatory process of
viral infection that is mediated by viral glycoproteins
[1–3]. The initial steps of HIV-1 infection of a target
cell (binding of the virus to the target cell and
fusion of the membranes of both) are mediated by
the viral envelope glycoprotein complex formed by
the transmembrane protein gp41 (responsible for
membrane fusion), and the surface protein gp120
(responsible for host recognition), bound to the external
domain of gp41 [4]. Entry of the HIV into a target cell is
performed in three steps: (i) binding of the viral gp120
to the target cell surface protein CD4 (a protein present
in helper T-cells and involved in the immunologic
response), a critical step for the attachment of the virus
particle to the target cell [5]; (ii) this process changes
the conformation of gp120 enabling this protein to bind
to yet another receptor on the immune system cell’s
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surface, typically CCR5 [6] or CXCR4 [7]; and (iii) gp41-
mediated membrane fusion [4]. The previous processes,
mediated by gp120, result in a conformational change
in gp41, which exposes a fusion peptide and allows it
to insert into the membrane of the target cell, hence
leading to the fusion of the two membranes and the
entry of the viral components into the target cell [4,8].
Several peptides based on the C-region of the HIV gp41
have been used in clinical trials as possible HIV fusion
inhibitors [reviewed in [9]]. Among these are T-1249 [10]
and T-20, also known as enfurvitide [11–13] (Figure 1).
T-20 is a synthetic 36-amino-acid peptide whose
sequence is homologous to the C-terminal of HR2
(Heptad Repeat 2) of gp41 [11]. This first generation
peptide is currently one of the more advanced clinical
drugs for inhibiting HIV-1 entry and has received fast
Food and Drugs Administration (FDA) approval [14,15].
Despite T-20’s effectiveness it has, already, encountered
some resistant strains of HIV [12,15].
T-1249 is a synthetic 39-amino-acid peptide com-
posed of sequences derived from HIV-1, HIV-2, and
Simian immunodeficiency virus (SIV) [10]. This fusion
inhibitor is in phase II clinical trials, and both phase
I and II clinical trials have shown that it is a stronger
inhibitor of HIV entry than T-20 and it retains function
against T-20 resistant strains [10,12,13].
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Figure 1 Sequence comparison of the four peptides under study. Homology between all the peptides (black bar) and between
T-20 and T-1249 (white bar) is highlighted.
Despite recent works, a detailed molecular picture of
the inhibitory mechanism promoted by these molecules
is still lacking. Working models for their mecha-
nisms of action, based mainly on fluorescence spec-
troscopy data, were presented in [16] (T-20) and [17]
(T-1249). Both schemes rely on the experimentally
verified efficient partition of the two peptides to zwit-
terionic bilayers, and differences between them arise
from the possibility of T-1249 (but not T-20) adsorb-
ing to cholesterol-rich membranes, which might be the
main cause of its improved efficiency (see Ref. 17 for a
detailed discussion).
T-20 and T-1249 are usually depicted, at least partly,
as α-helices by analogy with the structure of the
sequences with which they are homologous. However,
this representation is most probably not accurate for an
aqueous environment. The presence of a large number
of hydrophobic amino-acid residues in the sequence of
both peptides (Figure 1) would cause them, in solution,
to fold in order to form more globular structures that
would improve their solubility. This fact has been
observed for both T-20 and T-1249 by CD spectroscopy
[17]. These peptides also have the ability to interact
with/partition to cell membranes and their mode of
action depends partly on that property. However, both
fusion inhibitors in this study are endovenous drugs
and, as such, knowledge of their structure and behavior
in solution would help our understanding of their mode
of action.
In this work, we study the structure and behavior of
these two peptides in solution using MD simulations
in the 100 ns time scale. This was done also with the
aim of determining models of the two fusion inhibitors
that could be used to study their interaction with model
membranes. Two smaller model peptides, 3f5 and CTP
(Figure 1), homologous with both fusion inhibitors in
study, were also investigated with the same approach.
The use of smaller peptides allows for longer simulated
time ranges and hence for the study of longer time
scale properties. In this way, 3f5 and CTP were studied
to determine whether the studied 100-ns time range
was sufficient or if there was the need to extend the
study to longer time ranges.
METHODS
Initial models of the four peptides (α-helices) were built with the
Arguslab 4.01 package [18] and solvated in cubic simulation
boxes with SPC water [19], with dimensions and water content
proportional to the size of the peptide in question (the distance
between each molecule and the box walls is 0.5 nm): 3f5
was simulated in a box of 3.45 × 3.45 × 3.45 nm3 with 1278
water molecules, CTP in a box of 4.54 × 4.54 × 4.54 nm3 with
2964 water molecules, T-20 in a box of 7.19 × 7.19 × 7.19 nm3
with 12 160 water molecules, and T-1249 in a box of
7.41 × 7.41 × 7.41 nm3 with 13 330 water molecules. The
Gromacs 3.3.1 simulation package was used to perform all
the MD simulations [20,21]. The force field used to describe
the peptide interactions was the Gromos96 43a1 force field
[22, 23]. Prior to the MD simulation, the four systems
underwent a steepest-descent energy minimization of the
structure, followed by a small MD run with restraints in
the peptide atoms positions to properly allow the solvent
molecules to adjust/relax around the peptide. Restraints
were subsequently removed, and extensive (100 ns) molecular
dynamics simulations were then performed under constant
number of particles, pressure (1 bar), and temperature
(300 K), and using periodic boundary conditions. Pressure
and temperature control was carried out using the weak-
coupling Berendsen schemes [24], with coupling times of 1.0
and 0.1 ps, respectively. Isotropic pressure coupling was used.
All bonds were constrained to their equilibrium values, using
the SETTLE algorithm [25] for water and the LINCS algorithm
[26] for all other bonds. This approach allowed the use of a
time-step of 2 fs. Cutoffs of 1 nm were used in the treatment
of electrostatic interactions. Although this is not the most
accurate treatment for this type of long range interactions, it
allowed the study of longer time scales in a more reasonable
computer simulation time. The monitored parameters include
the root mean square deviation (RMSD) relative to the initial
conformation, radius of gyration (RG), secondary structure
(SS), and solvent accessible surface (SAS). RMSD and RG were
calculated using Gromacs 3.3.1 analysis packages [20, 21],
whereas SS and SAS were computed using the DSSP program
[27].
RESULTS AND DISCUSSION
In the time scale studied, all the peptides evolve roughly
in a similar fashion from the α-helix initial model to a
more or less globular flexible structure. This evolution
occurs in two stages. In the first stage (t < 25 ns), the
peptides rapidly change in conformation. This is clearly
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shown in the time dependence of the RMSDs which
have a larger variation in this time frame (Figure 2),
thus suggesting this rapid structural change. The RGs,
as a measure of the size of the peptide, also have
a substantial decrease in this first stage (Figure 3),
thus reflecting a change from an α-helix to a more
globular structure. All peptides evolve away from the
initial models into globular structures (see Figure 4
for typical snapshots of these) that are more capable
of protecting the more hydrophobic residues from the
solvent, therefore stabilizing the structure in solution.
Comparing T-20 with T-1249, it can be seen from
Figure 4 that the changes in secondary structure
away from the α-helical initial model are especially
rapid in the former. This is a first indication of the
experimentally verified [17] increased helicity of T-1249
relative to T-20 (but see also below).
This first stage of the folding of these peptides
is followed by a second stage (t > ∼25) of smoother
evolution in which they adopt a number of different
globular flexible structures that interchange between
one another (see snapshots and SS evolution in
Figure 4). This is also apparent in the time variations of
the RMSD (Figure 2), RG (Figure 3), and SAS (Figures 5
and 6) for all peptides, with the exception of CTP.
For the latter molecule, these properties suffer larger
variations in the first 25 ns and afterwards fluctuate
around an average value. In comparison with the
other peptides, the RMSDs plot of CTP shows smaller
fluctuations (Figure 2), and it also shows a considerable
helical content. This different behavior may be related
to the additional six residues located in its C-terminal
(Figure 1) that may be helping the its structure to
stabilize and form the α-helix. By comparison, 3f5,
which does not possess these residues, behaves in
much the same way as the other peptides, with the
exception of the T-1249’s N-terminus behavior that also
shows moderate helical content. This behavior seems
to be important, since it was observed in a recent report
that helix-stabilized HIV-1 fusion inhibitor peptides
Figure 2 Root mean square deviation relative to each model’s
initial conformation (α-helix structures in all cases).
Figure 3 Radius of gyration as a function of time for each
peptide under study.
were more active than T-20 – as much as 3600-fold
[28]. However, further studies with a wider variety of
peptides would be required to better understand these
results. In particular, the absence of inhibitory activity
in CTP in spite of the stability of its helical structure
(and 14-amino-acid homology with T-20), suggests that
this is not the single factor influencing the peptide’s
inhibitory activity.
To investigate if the lack of a stable structure for the
fusion inhibitors and 3f5 in our simulations was due
to a limitation in the time scale simulated, we carried
out longer simulations of 3f5 (500 ns). No change in the
described structural pattern was apparent, ruling out
time scale problems in this matter.
Both the SAS of each residue (Figure 5) and the SS
of T-20 and T-1249 (Figure 4) vary significantly dur-
ing the simulation time. The average content of α-helix
for the last 75 ns of each simulation of these peptides
was calculated and was found to be negligible for T-20
and 16.4% for T-1249 in qualitative accordance with
experimental data obtained by Veiga and coworkers
by CD spectroscopy measurements [17]. These authors
measured 8 and 30% of α-helical content in buffer,
for T-20 and T-1249, respectively. The higher results
obtained in their study may be related to the intrinsic
differences between the recovery of secondary structure
from CD spectra (only three types of structures are rec-
ognized [29]) and the SS analysis of our atomistic MD
simulations (which differentiates 8 types of secondary
structures [27]). An alternative explanation is that the
studied time scale is insufficient for secondary struc-
ture analysis, and that structural changes may occur
in longer time scales.
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Figure 4 Secondary structure as a function of time of the four peptides under study. Insets: snapshots of each peptide’s model
structure taken at 75 and 100 ns.
Figure 5 Solvent accessible surface as a function of time for each residue. Homology between peptides is highlighted as in
Figure 1.
CONCLUSIONS
Our results show that the studied peptides have
no stable structure in solution in the studied time
scale, and also that these peptides, especially the
fusion inhibitors, may assume not only one, but
several possible sets of structures in solution, some
of which are probably extensively solvated, whereas
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Figure 6 Total solvent accessible surface as a function of
time, for each peptide under study.
others might be better suited to interact with cell or
model membranes. These properties suit the inhibitor
peptides to the function they were designed for, as
they should be sufficiently soluble, but still capable
of interacting, adsorbing and/or incorporating into
lipid membranes. Molecular models of the interactions
of both T-20 and T-1249 with model membranes
were proposed by Veiga and coworkers [16,17]. Their
results show that both T-20 and T-1249 are able to
partition to the host membrane. Translocation should
be impossible because of charge effects. Furthermore,
T-1249 should be able to interact more strongly with
cholesterol-rich surfaces, such as lipid rafts, where
HIV-1 receptor CD4 and coreceptors CXCR4/CCR5
are considered to be located [30] (this may account
for its higher efficiency in inhibiting the fusion of
the virus, as suggested in [17]). To evaluate these
hypotheses, simulations of the interactions of the fusion
inhibitor peptides with model membranes of varying
composition are underway. One of the main goals
of the present study was to obtain realistic models
of the inhibitory peptides in aqueous solution that
could be used as starting points for simulations of the
peptides in presence of model membranes. In this way,
T-1249 is currently being simulated in the presence
of a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
bilayer. Using the final structure of the peptide in this
study as starting point, located in water ∼2 nm above
the lipid/water interface, a preliminary observation
of the trajectory under calculation points to a rapid
adsorption of the peptide to the surface of the model
membrane (t < 4–5 ns; data not shown). The possibility
of effective peptide incorporation for longer times is
being investigated.
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